Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Hashimoto

Showing results (251-260 of 330) with videos related to

Pageof 33
Sort By:
International Journal of Clinical Oncology|October 20, 2020
Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study)Tomoko Hamaya, Shingo Hatakeyama, Masaki Momota, et al.
Clinical Genitourinary Cancer|February 18, 2019
Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell CarcinomaKazutaka Okita, Shingo Hatakeyama, Toshiaki Tanaka, et al.
Thescientificworldjournal|April 18, 2014
Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomyTakuya Koie, Chikara Ohyama, Jotaro Mikami, et al.
Clinical Genitourinary Cancer|August 17, 2019
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective StudySakae Konishi, Shingo Hatakeyama, Kazuyuki Numakura, et al.
Cancers|December 23, 2022
Utility of the Age Discrepancy between Frailty-Based Biological Age and Expected Life Age in Patients with Urological CancersKyo Togashi, Shingo Hatakeyama, Osamu Soma, et al.
International Urology and Nephrology|September 20, 2018
Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institutionNaoki Fujita, Takuya Koie, Yasuhiro Hashimoto, et al.
Medical Oncology (Northwood, London, England)|November 27, 2018
Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysisSakae Konishi, Shingo Hatakeyama, Toshiaki Tanaka, et al.
Urologic Oncology|July 21, 2020
Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study)Hirotake Kodama, Shingo Hatakeyama, Masaki Momota, et al.
Thescientificworldjournal|November 15, 2013
Prognosis of elderly Japanese patients aged ≥80 years undergoing hemodialysisShingo Hatakeyama, Hiromi Murasawa, Itsuto Hamano, et al.
BJUI Compass|April 27, 2022
The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinomaKai Ozaki, Shingo Hatakeyama, Toshikazu Tanaka, et al.
Pageof 33

Showing results (251-260 of 330) with videos related to

Sort By:
Pageof 33
International Journal of Clinical Oncology|October 20, 2020
Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study)Tomoko Hamaya, Shingo Hatakeyama, Masaki Momota, et al.
Clinical Genitourinary Cancer|February 18, 2019
Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell CarcinomaKazutaka Okita, Shingo Hatakeyama, Toshiaki Tanaka, et al.
Thescientificworldjournal|April 18, 2014
Preoperative butyrylcholinesterase level as an independent predictor of overall survival in clear cell renal cell carcinoma patients treated with nephrectomyTakuya Koie, Chikara Ohyama, Jotaro Mikami, et al.
Clinical Genitourinary Cancer|August 17, 2019
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective StudySakae Konishi, Shingo Hatakeyama, Kazuyuki Numakura, et al.
Cancers|December 23, 2022
Utility of the Age Discrepancy between Frailty-Based Biological Age and Expected Life Age in Patients with Urological CancersKyo Togashi, Shingo Hatakeyama, Osamu Soma, et al.
International Urology and Nephrology|September 20, 2018
Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institutionNaoki Fujita, Takuya Koie, Yasuhiro Hashimoto, et al.
Medical Oncology (Northwood, London, England)|November 27, 2018
Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysisSakae Konishi, Shingo Hatakeyama, Toshiaki Tanaka, et al.
Urologic Oncology|July 21, 2020
Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study)Hirotake Kodama, Shingo Hatakeyama, Masaki Momota, et al.
Thescientificworldjournal|November 15, 2013
Prognosis of elderly Japanese patients aged ≥80 years undergoing hemodialysisShingo Hatakeyama, Hiromi Murasawa, Itsuto Hamano, et al.
BJUI Compass|April 27, 2022
The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinomaKai Ozaki, Shingo Hatakeyama, Toshikazu Tanaka, et al.
Pageof 33